<DOC>
	<DOCNO>NCT01008098</DOCNO>
	<brief_summary>The objective current study 1. evaluate efficacy escitalopram treatment post-traumatic stress disorder , 2. find structural change brain use magnetic resonance image association symptom reduction , 3. look difference brain imaging finding symptom change accord genetic difference brain-derived neurotrophic factor ( biological molecule facilitate neuronal growth human ) .</brief_summary>
	<brief_title>Neuroprotective/Neurotrophic Effect LexaproÂ® Patients With Posttraumatic Stress Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>1865 yearold male female PTSD diagnose SCIDIV Previous current treatment history PTSD Neurologic disease ( eg. , epilepsy , infarct , multiple sclerosis , brain tumor ) Any axis I psychiatric disorder diagnose SCIDIV Borderline personality disorder antisocial personality disorder IQ 80 Any contraindication MRI scan Any current psychotropic medication Unstable medical illness severe abnormality laboratory test screen assessment Women pregnant , breastfeeding , plan pregnancy Any contraindication drug use study ( e.g. , allergy , intolerance , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Posttraumatic Stress Disorder</keyword>
	<keyword>Escitalopram</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>BDNF</keyword>
</DOC>